Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Shares (Diluted)

Shares (Diluted) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
164.9M+3.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
100.6M+4.5%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
21.5M+7.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
28.7M-6.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
194.8M+2.4%
PVL
Palvella TherapeuticsPVLA
13.1M+18.8%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's shares (diluted)?
BioCryst Pharmaceuticals (BCRX) reported shares (diluted) of 242.3M in Q1 2026.
How has BioCryst Pharmaceuticals's shares (diluted) changed year-over-year?
BioCryst Pharmaceuticals's shares (diluted) increased by 12.5% year-over-year, from 215.3M to 242.3M.
What is the long-term trend for BioCryst Pharmaceuticals's shares (diluted)?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's shares (diluted) has grown at a 5.2% compound annual growth rate (CAGR), from 713.7M to 873.6M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.